
## Michael M Lederman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2034904/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviralâ€Treated HIV Infection. Journal of Infectious Diseases, 2009, 199, 1177-1185.	4.0	527
2	HIV-Infected Individuals with Low CD4/CD8 Ratio despite Effective Antiretroviral Therapy Exhibit Altered T Cell Subsets, Heightened CD8+ T Cell Activation, and Increased Risk of Non-AIDS Morbidity and Mortality. PLoS Pathogens, 2014, 10, e1004078.	4.7	495
3	Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non–AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment. Journal of Infectious Diseases, 2014, 210, 1248-1259.	4.0	464
4	Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. Journal of Infectious Diseases, 2014, 210, 1228-1238.	4.0	395
5	Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5. Science, 2004, 306, 485-487.	12.6	364
6	Residual Immune Dysregulation Syndrome in Treated HIV infection. Advances in Immunology, 2013, 119, 51-83.	2.2	295
7	Oral Mycobiome Analysis of HIV-Infected Patients: Identification of Pichia as an Antagonist of Opportunistic Fungi. PLoS Pathogens, 2014, 10, e1003996.	4.7	278
8	Immunologic Failure Despite Suppressive Antiretroviral Therapy Is Related to Activation and Turnover of Memory CD4 Cells. Journal of Infectious Diseases, 2011, 204, 1217-1226.	4.0	265
9	Biology of CCR5 and Its Role in HIV Infection and Treatment. JAMA - Journal of the American Medical Association, 2006, 296, 815.	7.4	219
10	Pretreatment Levels of Soluble Cellular Receptors and Interleukinâ€6 Are Associated with HIV Disease Progression in Subjects Treated with Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2010, 201, 1796-1805.	4.0	124
11	The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood, 2013, 121, 4635-4646.	1.4	117
12	CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection. Clinical Infectious Diseases, 2016, 62, 392-396.	5.8	114
13	SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. EBioMedicine, 2020, 58, 102907.	6.1	110
14	IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. Journal of Clinical Investigation, 2016, 126, 2745-2756.	8.2	97
15	Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 154-160.	2.1	85
16	Inflammatory Cytokines Drive CD4+ T-Cell Cycling and Impaired Responsiveness to Interleukin 7: Implications for Immune Failure in HIV Disease. Journal of Infectious Diseases, 2014, 210, 619-629.	4.0	77
17	Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population. JAMA Network Open, 2019, 2, e1916526.	5.9	77
18	IL-7 Induces SAMHD1 Phosphorylation in CD4+ T Lymphocytes, Improving Early Steps of HIV-1 Life Cycle. Cell Reports, 2016, 14, 2100-2107.	6.4	64

2

Michael M Lederman

#	Article	IF	CITATIONS
19	Cytokines and T-Cell Homeostasis in HIV Infection. Journal of Infectious Diseases, 2016, 214, S51-S57.	4.0	62
20	Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 483-492.	2.1	59
21	CD8 T cell persistence in treated HIV infection. Current Opinion in HIV and AIDS, 2014, 9, 500-505.	3.8	56
22	Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248. Journal of Infectious Diseases, 2013, 208, 884-891.	4.0	53
23	Determinants of Protection among HIVâ€Exposed Seronegative Persons: An Overview. Journal of Infectious Diseases, 2010, 202, S333-S338.	4.0	49
24	Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy–mediated Viral Suppression. Clinical Infectious Diseases, 2019, 69, 676-686.	5.8	49
25	Coagulation and morbidity in treated HIV infection. Thrombosis Research, 2014, 133, S21-S24.	1.7	45
26	Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-NaÃ <sup>-</sup> ve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine. PLoS ONE, 2013, 8, e83514.	2.5	45
27	Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. Clinical Infectious Diseases, 2019, 68, 1877-1886.	5.8	42
28	Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop. Pathogens and Immunity, 2020, 5, 143.	3.1	42
29	Altered Monocyte and Endothelial Cell Adhesion Molecule Expression Is Linked to Vascular Inflammation in Human Immunodeficiency Virus Infection. Open Forum Infectious Diseases, 2016, 3, ofw224.	0.9	41
30	Vitamin D, d -dimer, Interferon Î <sup>3</sup> , and sCD14 Levels are Independently Associated with Immune Reconstitution Inflammatory Syndrome: A Prospective, International Study. EBioMedicine, 2016, 4, 115-123.	6.1	37
31	Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV. Pathogens and Immunity, 2017, 2, 376.	3.1	36
32	A Cure for HIV Infection: "Not in My Lifetime―or "Just Around the Corner�. Pathogens and Immunity, 2016, 1, 154.	3.1	35
33	Inflammatory Function of CX3CR1 <sup>+</sup> CD8 <sup>+</sup> T Cells in Treated HIV Infection Is Modulated by Platelet Interactions. Journal of Infectious Diseases, 2016, 214, 1808-1816.	4.0	35
34	Translocated microbiome composition determines immunological outcome in treated HIV infection. Cell, 2021, 184, 3899-3914.e16.	28.9	35
35	Altered Lipidome Composition Is Related to Markers of Monocyte and Immune Activation in Antiretroviral Therapy Treated Human Immunodeficiency Virus (HIV) Infection and in Uninfected Persons. Frontiers in Immunology, 2019, 10, 785.	4.8	34
36	Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes. Blood, 2013, 121, 2914-2922.	1.4	31

#	Article	IF	CITATIONS
37	Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. Journal of Infectious Diseases, 2018, 218, 239-248.	4.0	29
38	Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1–infected individuals with low-density lipoprotein cholesterol <130Âmg/dL (AIDS Clinical Trials Group Study A5275). Journal of Clinical Lipidology, 2017, 11, 61-69.	1.5	27
39	â€~Rinse and Replace': Boosting T Cell Turnover To Reduce HIV-1 Reservoirs. Trends in Immunology, 2020, 41, 466-480.	6.8	26
40	Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy. PLoS ONE, 2015, 10, e0139474.	2.5	25
41	Telmisartan Therapy Does Not Improve Lymph Node or Adipose Tissue Fibrosis More Than Continued Antiretroviral Therapy Alone. Journal of Infectious Diseases, 2018, 217, 1770-1781.	4.0	23
42	Cytomegalovirus Coinfection Is Associated with Increased Vascular-Homing CD57+ CD4 T Cells in HIV Infection. Journal of Immunology, 2020, 204, 2722-2733.	0.8	23
43	Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection. Retrovirology, 2008, 5, 116.	2.0	22
44	A Phase I/II Evaluation of Oral Lâ€2â€Oxothiazolidineâ€4â€Carboxylic Acid in Asymptomatic Patients Infected with Human Immunodeficiency Virus. Journal of Clinical Pharmacology, 1998, 38, 357-363.	2.0	21
45	Fingolimod retains cytolytic T cells and limits T follicular helper cell infection in lymphoid sites of SIV persistence. PLoS Pathogens, 2019, 15, e1008081.	4.7	21
46	Physical Activity Intensity is Associated with Symptom Distress in the CNICS Cohort. AIDS and Behavior, 2019, 23, 627-635.	2.7	21
47	Macrophage maturation from blood monocytes is altered in people with HIV, and is linked to serum lipid profiles and activation indices: A model for studying atherogenic mechanisms. PLoS Pathogens, 2020, 16, e1008869.	4.7	21
48	CD161 Expression on Mucosa-Associated Invariant T Cells is Reduced in HIV-Infected Subjects Undergoing Antiretroviral Therapy Who Do Not Recover CD4+ T Cells. Pathogens and Immunity, 2017, 2, 335.	3.1	21
49	SIV/SHIV Infection Triggers Vascular Inflammation, Diminished Expression of Krüppel-like Factor 2 and Endothelial Dysfunction. Journal of Infectious Diseases, 2016, 213, 1419-1427.	4.0	20
50	Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. Vaccine, 2018, 36, 453-460.	3.8	19
51	CD56bright NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections. Journal of Leukocyte Biology, 2017, 102, 171-184.	3.3	18
52	"Inflammescent" CX3CR1+CD57+ CD8 T cells are generated and expanded by IL-15. JCI Insight, 2020, 5, .	5.0	18
53	CX3CL1 and IL-15 Promote CD8 T cell chemoattraction in HIV and in atherosclerosis. PLoS Pathogens, 2020, 16, e1008885.	4.7	17
54	Markers of inflammation and immune activation are associated with lung function in a multi-center cohort of persons with HIV. Aids, 2021, 35, 1031-1040.	2.2	15

MICHAEL M LEDERMAN

#	Article	IF	CITATIONS
55	Plasmacytoid Dendritic Cells Mediate Synergistic Effects of HIV and Lipopolysaccharide on CD27 <sup>+</sup> IgD <sup>–</sup> Memory B Cell Apoptosis. Journal of Virology, 2014, 88, 11430-11441.	3.4	14
56	Interferon-αinhibits CD4 T cell responses to interleukin-7 and interleukin-2 and selectively interferes with Akt signaling. Journal of Leukocyte Biology, 2015, 97, 1139-1146.	3.3	14
57	Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 389-397.	2.4	14
58	CD8+ T-Cell–Derived Tumor Necrosis Factor Can Induce Tissue Factor Expression on Monocytes. Journal of Infectious Diseases, 2019, 220, 73-77.	4.0	14
59	Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control. Journal of Infectious Diseases, 2022, 225, 1040-1049.	4.0	13
60	Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity. Antiviral Therapy, 2016, 22, 71-75.	1.0	11
61	Effect of IL-7 Therapy on Phospho-Ribosomal Protein S6 and TRAF1 Expression in HIV-Specific CD8 T Cells in Patients Receiving Antiretroviral Therapy. Journal of Immunology, 2018, 200, 558-564.	0.8	11
62	Antiretroviral Treatment for HIV Elite Controllers?. Pathogens and Immunity, 2020, 5, 121.	3.1	11
63	Identification of Occult Fusobacterium nucleatum Central Nervous System Infection by Use of PCR-Electrospray Ionization Mass Spectrometry. Journal of Clinical Microbiology, 2014, 52, 3462-3464.	3.9	9
64	HIV infection is associated with elevated biomarkers of immune activation in Ugandan adults with pneumonia. PLoS ONE, 2019, 14, e0216680.	2.5	9
65	Ten Years HIV Free: An Interview with "The Berlin Patient,―Timothy Ray Brown. Pathogens and Immunity, 2017, 2, 422.	3.1	9
66	Pneumoproteins are associated with pulmonary function in HIV-infected persons. PLoS ONE, 2019, 14, e0223263.	2.5	8
67	Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy. Aids, 2021, 35, 2489-2495.	2.2	7
68	Haemophilia, human immunodeficiency virus and human immunodeficiency virus pathogenesis. Thrombosis and Haemostasis, 2010, 104, 911-914.	3.4	5
69	Lymphocyte Counts are Dynamic and Associated with Survival after Transcatheter Aortic Valve Replacement. Structural Heart, 2018, 2, 557-564.	0.6	5
70	A surprising role for TLR7. Nature Immunology, 2015, 16, 8-9.	14.5	4
71	Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquine. Clinical Infectious Diseases, 2018, 67, 1617-1620.	5.8	4
72	Highly oxidized lowâ€density lipoprotein mediates activation of monocytes but does not confer interleukinâ€1 β secretion nor interleukinâ€15 transpresentation function. Immunology, 2020, 159, 221-230.	4.4	3

## MICHAEL M LEDERMAN

#	Article	IF	CITATIONS
73	Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. Pathogens and Immunity, 2017, 2, 151.	3.1	3
74	Monitoring Circulating Immune Checkpoint Proteins as Predictors of Non-AIDS Morbid Events in People With HIV Initiating Antiretroviral Therapy. Open Forum Infectious Diseases, 2022, 9, ofab570.	0.9	3
75	Anisocytosis and leukocytosis are independently related to survival after transcatheter aortic valve replacement. Journal of Cardiovascular Medicine, 2018, 19, 191-194.	1.5	2
76	Plasma lipidome abnormalities in people with HIV initiating antiretroviral therapy. Translational Medicine Communications, 2020, 5, .	1.4	1
77	AIDS in the Heartland–Hemophilia Was the Harbinger of Things to Come. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 517-522.	2.1	1
78	Compulsory Immunization Protects Against Infection: What Law and Society Can Do. Pathogens and Immunity, 2020, 5, 1.	3.1	1
79	Is France Once Again Looking for a Scapegoat?. Pathogens and Immunity, 2021, 6, 149-152.	3.1	1
80	Stability of plasma indices of inflammation/coagulation and homeostasis after fatty and non-fatty meals in treated people with HIV. Journal of Virus Eradication, 2019, 5, 28-32.	0.5	0
81	Charles C. J. Carpenter Jr (1931–2020). Journal of Infectious Diseases, 0, , .	4.0	0
82	Stability of plasma indices of inflammation/coagulation and homeostasis after fatty and non-fatty meals in treated people with HIV. Journal of Virus Eradication, 2019, 5, 28-32.	0.5	0